Rapid generation of human antibodies that neutralize SARS-CoV-2.
The success of vaccines generally depends on the generation of antibodies, also known as immunoglobulins, which are proteins that circulate in the blood and that, when they recognise foreign substances such as viruses, neutralise them (i.e. reduce or cancel out their effect), preventing their spread
The short reaction time to the pandemic makes methods such as the transfer of already selected antibodies appear to be the best strategy. This project proposes the generation of ready-to-use human antibodies, allowing the treatment of current and future patients.
Principal Investigator: Balbino Alarcón Sánchez (CBM)